Lupin is currently trading at Rs. 870.65, up by 7.80 points or 0.90% from its previous closing of Rs. 862.85 on the BSE.
The scrip opened at Rs. 865.00 and has touched a high and low of Rs. 873.00 and Rs. 865.00 respectively. So far 13501 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 955.85 on 15-Jun-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 919.00 and Rs. 846.30 respectively. The current market cap of the company is Rs. 39094.96 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.88% and 12.91% respectively.
Lupin has received tentative approval for its Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
Empagliflozin and Linagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg (RLD: Glyxambi) had an annual sales of approximately $242 million in the U.S. (IQVIA MAT Mar 2020).
Lupin is an innovation led transnational pharmaceutical company headquartered in Mumbai, India.
